Symbolic bisimulation for quantum processes

With the previous notions of bisimulation presented in literature, to check if two quantum processes are bisimilar, we have to instantiate the free quantum variables of them with arbitrary quantum states, and verify the bisimilarity of resultant configurations. This makes checking bisimilarity infeasible from an algorithmic point of view because quantum states constitute a continuum. In this paper, we introduce a symbolic operational semantics for quantum processes directly at the quantum operation level, which allows us to describe the bisimulation between quantum processes without resorting to quantum states. We show that the symbolic bisimulation defined here is equivalent to the open bisimulation for quantum processes in the previous work, when strong bisimulations are considered. An algorithm for checking symbolic ground bisimilarity is presented. We also give a modal logical characterisation for quantum bisimilarity based on an extension of Hennessy-Milner logic to quantum processes.Comment: 30 pages, 7 figures, comments are welcom

Human Resource Flow and Software Firm Performance: The Role of Direct vs. Indirect Competitors

Recent years have witnessed increasingly stiff competition for talents among software firms. The economic impact of obtaining workers from or losing workers to competing firms, however, has rarely been quantified. Built on the literature of human resource flow and firm competition, this study examines the impact of human resource flows from and to different types of competitors on company performance. In particular, we divide competitors into direct and indirect competitors according to their market and resource similarity. Using a large dataset on labour mobility derived from LinkedIn.com, we quantify the impact of employees who came from or joined direct and indirect competitors respectively. We find that employees from competitors bring great benefits to the recipient firms. Specifically, a 1 percent increase of the number of employees from direct (indirect) competitors that join the focal company in the previous year increases the company’s economic value added by 0.054 (0.074) percent in the current year. Our results also contribute to the existing literature on human resources and company strategy and provide practical implications to recruiters and policy makers in the software industry

Immunocompromised individuals are at increased risk of COVID‐19 breakthrough infection, hospitalization, and death in the post‐vaccination era: A systematic review

Introduction: Immunocompromised individuals have been shown to mount a reduced response to vaccination, resulting in reduced vaccine effectiveness in this cohort. Therefore, in the postvaccination era, immunocompromised individuals remain at high risk of breakthrough infection and COVID‐19 related hospitalization and death, which persist despite vaccination efforts. There has been a marked paucity of systematic reviews evaluating existing data describing the clinical measures of efficacy of COVID‐19 vaccination, specifically in immunocompromised populations. In particular, there is a scarcity of comprehensive evaluations exploring breakthrough infections and severe COVID‐19 in this patient population. Methods: To address this gap, we conducted a systematic review which aimed to provide a summary of current clinical evidence of the effectiveness of COVID‐19 vaccination in the immunocompromised population. Using PRISMA guidelines, we conducted a literature search on PubMed and the Cochrane database published between January 1, 2021 to September 1, 2022. Results: Our findings demonstrated that despite vaccination, immunocompromised patients remained at high risk of new breakthrough COVID‐19 infection and severe COVID‐19 outcomes compared to the general population. We found increased average relative risk (RR) of breakthrough infections in the immunocompromised population, including patients with cancer (RR = 1.4), HIV (RR = 1.92), chronic kidney disease (RR = 2.26), immunodeficiency (RR = 2.55), and organ transplant recipients (RR = 6.94). These patients are also at greater risk for hospitalizations and death following COVID‐19 breakthrough infection. We found that the RR of hospitalization and death in Cancer patients was 1.08 and 2.82, respectively. Conclusion: This demonstrated that vaccination does not offer an adequate level of protection in these groups, necessitating further measures such as Evusheld and further boosters

Immunocompromised individuals are at increased risk of COVID‐19 breakthrough infection, hospitalization, and death in the post‐vaccination era:A systematic review

Introduction: Immunocompromised individuals have been shown to mount a reduced response to vaccination, resulting in reduced vaccine effectiveness in this cohort. Therefore, in the postvaccination era, immunocompromised individuals remain at high risk of breakthrough infection and COVID‐19 related hospitalization and death, which persist despite vaccination efforts. There has been a marked paucity of systematic reviews evaluating existing data describing the clinical measures of efficacy of COVID‐19 vaccination, specifically in immunocompromised populations. In particular, there is a scarcity of comprehensive evaluations exploring breakthrough infections and severe COVID‐19 in this patient population. Methods: To address this gap, we conducted a systematic review which aimed to provide a summary of current clinical evidence of the effectiveness of COVID‐19 vaccination in the immunocompromised population. Using PRISMA guidelines, we conducted a literature search on PubMed and the Cochrane database published between January 1, 2021 to September 1, 2022. Results: Our findings demonstrated that despite vaccination, immunocompromised patients remained at high risk of new breakthrough COVID‐19 infection and severe COVID‐19 outcomes compared to the general population. We found increased average relative risk (RR) of breakthrough infections in the immunocompromised population, including patients with cancer (RR = 1.4), HIV (RR = 1.92), chronic kidney disease (RR = 2.26), immunodeficiency (RR = 2.55), and organ transplant recipients (RR = 6.94). These patients are also at greater risk for hospitalizations and death following COVID‐19 breakthrough infection. We found that the RR of hospitalization and death in Cancer patients was 1.08 and 2.82, respectively. Conclusion: This demonstrated that vaccination does not offer an adequate level of protection in these groups, necessitating further measures such as Evusheld and further boosters

Influence of green financing, technology innovation, and trade openness on consumptionbased carbon emissions in BRICS countries

The study explores the dynamic effects of renewable energy investment (green financing), green technology, and trade openness on consumption-based (trade-adjusted) carbon emissions in BRICS economies from 2000 to 2020. The study employs the cross-section autoregressive distributed lag method for empirical estimation to address slope heterogeneity and cross-sectional dependency issues in panel data. The findings exhibit that green financing and sustainable technologies mitigate consumption-based carbon emissions in the long-run, while trade openness contributes to emissions in BRICS countries. The short-run outcomes are compatible with long-run; however, the magnitude of long-run estimates is larger than the short-run. Moreover, the error correction term reveals a significant negative coefficient value, endorsing the conversion towards steady-state equilibrium with a 37% yearly adjustment rate in case of any deviation from equilibrium. The robustness of results is confirmed through augmented mean group and common correlated effect mean group. These findings imply that BRICS countries should encourage financing in renewable energy projects and allocate R&D investment to promote the adaptation of sustainable technologies. In addition, sustainable and green trade policies would help to curb trade-adjusted pollution